TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36058810

Group type: EXPERIMENTAL
Intervention: Biomarker use in treatment decisions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prospective trials and collaborative efforts
Number of subjects: 0
Study: 36058829

Group type: EXPERIMENTAL
Intervention: Patients with all segments with maxLCBI > 400
Number of subjects: 1550

Group type: COMPARATOR
Intervention: Patients with varying levels of maxLCBI
Number of subjects: 1550
Study: 36058925

Group type: EXPERIMENTAL
Intervention: Concentrated transdiagnostic, interdisciplinary group treatment delivered during 5 consecutive days.
Number of subjects: 42
Study: 36059138

Group type: EXPERIMENTAL
Intervention: Ceftaroline 600 mg every 12 hours
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Constant infusion of ceftaroline 50 mg/h after a loading dose of 600 mg
Number of subjects: 18
Study: 36059450

Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunotherapy (24 patients)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (16 patients)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Neoadjuvant targeted therapy (9 patients)
Number of subjects: 49
Study: 36059523

Group type: EXPERIMENTAL
Intervention: tandem CD19-CD22 based CAR-T cells
Number of subjects: 33
Study: 36060219

Group type: EXPERIMENTAL
Intervention: Participatory video intervention
Number of subjects: 0
Study: 36060221

Group type: EXPERIMENTAL
Intervention: High-dose vitamin A supplements and vitamin A-fortified foods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36060611

Group type: EXPERIMENTAL
Intervention: Xiaomi Mi Band for sleep monitoring
Number of subjects: 0
Study: 36060678

Group type: EXPERIMENTAL
Intervention: High-intensity interval training with hyperbaric oxygen (HBO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36061275

Group type: EXPERIMENTAL
Intervention: Self-management training (SMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neurofeedback (NF)
Number of subjects: 0
Study: 36061298

Group type: EXPERIMENTAL
Intervention: Alight app
Number of subjects: 63
Study: 36061300

Group type: EXPERIMENTAL
Intervention: Circulating microRNAs (miRNAs) quantified using ID3EAL™ miRNA Discovery Platform
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control group (non-relapsers)
Number of subjects: 217
Study: 36061336

Group type: EXPERIMENTAL
Intervention: Aficamten (≤50 mg single doses or ≤10 mg daily for 14 or 17 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36061421

Group type: EXPERIMENTAL
Intervention: Trans-obturator tape intervention, details on dosage and duration not available
Number of subjects: 0
Study: 36061551

Group type: EXPERIMENTAL
Intervention: Resting power/mass and E/e' ratio
Number of subjects: 475
Study: 36061555

Group type: EXPERIMENTAL
Intervention: Physiology-guided PCI
Number of subjects: 1322

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 1322

Group type: EXPERIMENTAL
Intervention: Angiography-Guided PCI
Number of subjects: 1322
Study: 36061598

Group type: EXPERIMENTAL
Intervention: 4-day accelerated continuous theta burst stimulation (cTBS) treatment
Number of subjects: 7
Study: 36061897

Group type: EXPERIMENTAL
Intervention: Moderately carbohydrate-restricted diet for 6 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Fixed body weight loss
Number of subjects: 72
Study: 36061986

Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied over the primary motor cortex of the undamaged hemisphere
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Healthy individuals
Number of subjects: 17
Study: 36062026

Group type: EXPERIMENTAL
Intervention: Natalizumab followed by alemtuzumab sequential therapy
Number of subjects: 0
Study: 36062046

Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 77
Study: 36062144

Group type: EXPERIMENTAL
Intervention: Multi-domain exercise intervention (WE-BFit)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 36062451

Group type: EXPERIMENTAL
Intervention: Remote patient management (RPM) with daily measurements of vital parameters under guidance of HF nurses.
Number of subjects: 1538

Group type: EXPERIMENTAL
Intervention: Remote patient management (RPM) with daily measurements of vital parameters.
Number of subjects: 1538
Study: 36062477

Group type: EXPERIMENTAL
Intervention: Trimethyllysine (TML)
Number of subjects: 2413

Group type: EXPERIMENTAL
Intervention: Higher plasma TML
Number of subjects: 2413

Group type: EXPERIMENTAL
Intervention: Plasma GBB
Number of subjects: 2413

Group type: EXPERIMENTAL
Intervention: Plasma TMAO
Number of subjects: 2413

Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate
Number of subjects: 2413
Study: 36062815

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 2012

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 2012

Group type: COMPARATOR
Intervention: No anticoagulant treatment
Number of subjects: 2012

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 2012

Group type: EXPERIMENTAL
Intervention: MPI values
Number of subjects: 2012

Group type: EXPERIMENTAL
Intervention: Higher scores in MPI
Number of subjects: 2012
Study: 36062869

Group type: EXPERIMENTAL
Intervention: JNJ-56136379 with itraconazole 200 mg (CYP3A inhibitor) for 21 days prior to dosing.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose estrogen-based contraceptives with JNJ-56136379
Number of subjects: 0
Study: 36062970

Group type: COMPARATOR
Intervention: Systemic corticosteroids plus intranasal corticosteroid/mucolytic/decongestant
Number of subjects: 30

Group type: COMPARATOR
Intervention: Palmitoylethanolamide plus luteolin
Number of subjects: 30
Study: 36063082

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 709

Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 709
Study: 36063364

Group type: COMPARATOR
Intervention: Intranasal corticosteroid spray
Number of subjects: 691

Group type: COMPARATOR
Intervention: Intranasal corticosteroid drops
Number of subjects: 691
Study: 36063533

Group type: EXPERIMENTAL
Intervention: Enhanced HIV testing services with features such as everyday testing availability, health checks, and STI examinations.
Number of subjects: 740

Group type: COMPARATOR
Intervention: Oral testing and provider-assisted confidential partner notification.
Number of subjects: 740
Study: 36063832

Group type: EXPERIMENTAL
Intervention: Azacitidine with venetoclax
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m²
Number of subjects: 23

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 23
Study: 36064386

Group type: EXPERIMENTAL
Intervention: Sintilimab (200 mg) plus docetaxel (75 mg/m2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sintilimab plus docetaxel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High PD-L1 expression in circulating tumor cells (CTC-PD-L1 ≥32.5%)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PD-L1 < 1% and CD8 ≥ 1% expression
Number of subjects: 30
Study: 36064395

Group type: EXPERIMENTAL
Intervention: Health literacy (HL) tailored practices implemented by healthcare professionals (HCPs)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Education and training of HCPs about health literacy (HL)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Engaging patients and their family
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Creating a multidisciplinary HCP interest group dedicated to HL
Number of subjects: 29
Study: 36064457

Group type: EXPERIMENTAL
Intervention: Safe Hands project intervention
Number of subjects: 3553
Study: 36064491

Group type: EXPERIMENTAL
Intervention: Epidural blood patch
Number of subjects: 643
Study: 36064577

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (alloHCT)
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 3234
Study: 36064599

Group type: EXPERIMENTAL
Intervention: CNS10-NPC-GDNF (human neural progenitor cells transduced with GDNF) transplanted unilaterally into the lumbar spinal cord
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CNS10-NPC-GDNF
Number of subjects: 18
Study: 36064670

Group type: EXPERIMENTAL
Intervention: IPV-Al (aluminium-adjuvanted reduced dose inactivated polio vaccine)
Number of subjects: 0
Study: 36064689

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 255
Study: 36064725

Group type: EXPERIMENTAL
Intervention: Miglustat use (a glucosylceramide synthase inhibitor)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NIH study duration (NIHSD)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Seizure history
Number of subjects: 120
Study: 36064748

Group type: EXPERIMENTAL
Intervention: Guided imagery for treatment (GIFT) - a brief, two-session guided imagery intervention.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) - control group.
Number of subjects: 0
Study: 36064785

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36064841

Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 222
Study: 36064878

Group type: EXPERIMENTAL
Intervention: C-terminal telopeptide of type I collagen (CTX-I)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Procollagen I N-terminal peptide (PINP)
Number of subjects: 73
Study: 36065356

Group type: EXPERIMENTAL
Intervention: TearCare
Number of subjects: 235

Group type: COMPARATOR
Intervention: LipiFlow
Number of subjects: 235
Study: 36066322

Group type: EXPERIMENTAL
Intervention: Independent, trained observers measuring ER distance
Number of subjects: 1
Study: 36066373

Group type: COMPARATOR
Intervention: Conventional chest physiotherapy (versus no physiotherapy)
Number of subjects: 974

Group type: COMPARATOR
Intervention: OMT (versus placebo)
Number of subjects: 974

Group type: COMPARATOR
Intervention: High-frequency chest wall oscillation (versus no physiotherapy)
Number of subjects: 974

Group type: COMPARATOR
Intervention: Active cycle of breathing techniques (versus no physiotherapy)
Number of subjects: 974

Group type: COMPARATOR
Intervention: Positive expiratory pressure (versus no physiotherapy)
Number of subjects: 974

Group type: COMPARATOR
Intervention: High-frequency chest wall oscillation plus fibrobronchoscope alveolar lavage (versus fibrobronchoscope alveolar lavage alone)
Number of subjects: 974
Study: 36066616

Group type: EXPERIMENTAL
Intervention: Frail patients
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Frail patients with dementia
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Lower age
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Immobility, loneliness, and weight loss
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Non-frail patients
Number of subjects: 696
Study: 36066618

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa (BA)
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Model-informed approach for management of bleeding AEs
Number of subjects: 936
Study: 36066745

Group type: EXPERIMENTAL
Intervention: Odevixibat treatment for 24 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: PRUCISION ObsRO instrument
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: ObsRO scores at week 24
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Sensitivity to change analysis
Number of subjects: 62
Study: 36066903

Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse 15 mg/kg/day for 3 days followed by oral prednisone 1 mg/kg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral prednisone 1 mg/kg/day alone
Number of subjects: 40
Study: 36066936

Group type: EXPERIMENTAL
Intervention: Weight management intervention with automated tailored text messages during months 1-6 for weight loss initiation and months 7-18 for weight maintenance.
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Partner-assisted weight management intervention with automated tailored text messages during months 1-6 for weight loss initiation and months 7-18 for weight maintenance.
Number of subjects: 462
Study: 36066958

Group type: EXPERIMENTAL
Intervention: 8-week transdiagnostic ICBT course (Wellbeing Course for New Moms)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 63
Study: 36066965

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 0
Study: 36066967

Group type: EXPERIMENTAL
Intervention: PARTNER-MH intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 50
Study: 36067063

Group type: EXPERIMENTAL
Intervention: Daratumumab subcutaneous (DARA SC) 1800 mg every 4 weeks
Number of subjects: 192

Group type: COMPARATOR
Intervention: Daratumumab intravenous (DARA IV)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Daratumumab subcutaneous (DARA SC)
Number of subjects: 192
Study: 36067139

Group type: EXPERIMENTAL
Intervention: Physiotherapy interventions recommended by physiotherapists (education, spinal exercises, manual therapy)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Passive physiotherapy approaches prescribed by general practitioners (massage therapy, electrotherapy)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Overall agreement for diagnosis or reason of referral
Number of subjects: 300

Group type: COMPARATOR
Intervention: Compliance with evidence-based recommendations
Number of subjects: 300
Study: 36067271

Group type: EXPERIMENTAL
Intervention: Psychological adjustment and adaptation interventions; specific details not available
Number of subjects: 0
Study: 36067410

Group type: EXPERIMENTAL
Intervention: Telerehabilitation training with handheld or stand optical magnifier or portable electronic magnifier
Number of subjects: 14
Study: 36068495

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) administered for six two-weekly cycles prior to chemoradiotherapy.
Number of subjects: 128
Study: 36068503

Group type: EXPERIMENTAL
Intervention: CMR-positive myocarditis (group A), 12 patients (25.5%)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: CMR-negative myocarditis (group B), 35 patients (74.5%)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Serological analysis for cardiotropic viruses
Number of subjects: 51
Study: 36068611

Group type: EXPERIMENTAL
Intervention: Nurse case management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remote blood pressure (BP) monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social determinants of health (SDoH) support
Number of subjects: 0
Study: 36068647

Group type: EXPERIMENTAL
Intervention: quintuply-fortified salt with iron in the form of encapsulated ferrous fumarate, zinc, vitamin B12, folic acid, and iodine (eFF-Q5S)
Number of subjects: 1248

Group type: EXPERIMENTAL
Intervention: quintuply-fortified salt with iron in the form of ferric pyrophosphate plus EDTA, zinc, vitamin B12, folic acid, and iodine (FePP-Q5S)
Number of subjects: 1248

Group type: COMPARATOR
Intervention: iodized salt (IS)
Number of subjects: 1248

Group type: EXPERIMENTAL
Intervention: quintuply-fortified salt (MFS)
Number of subjects: 1248
Study: 36068858

Group type: EXPERIMENTAL
Intervention: Vortioxetine treatment for MDD (6 months)
Number of subjects: 184
Study: 36068950

Group type: EXPERIMENTAL
Intervention: Bispecific LV20.19 CAR T-cell therapy at a target dose of 2.5 × 10^6 cells/kg
Number of subjects: 0
Study: 36069000

Group type: EXPERIMENTAL
Intervention: Original QOC EOL subscale
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Adapted QOC EOL subscale
Number of subjects: 56
Study: 36069141

Group type: EXPERIMENTAL
Intervention: Seasonal respiratory viral infection
Number of subjects: 3931

Group type: EXPERIMENTAL
Intervention: Respiratory syncytial virus (RSV)
Number of subjects: 3931
Study: 36069336

Group type: EXPERIMENTAL
Intervention: Magnetic resonance enterocolonography (MREC)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Pan-enteric capsule endoscopy (CE)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Ileocolonoscopy (IC)
Number of subjects: 153
Study: 36069495

Group type: EXPERIMENTAL
Intervention: rFSH (150 IU daily)
Number of subjects: 366
Study: 36069781

Group type: EXPERIMENTAL
Intervention: Adapted REBOOT intervention
Number of subjects: 10
Study: 36069838

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Light physical activity (LPA)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Changes in movement behaviors
Number of subjects: 273
Study: 36070087

Group type: EXPERIMENTAL
Intervention: Children born VLBW
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Children born VLBW classified as vulnerable
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Apgar <7
Number of subjects: 77
Study: 36070134

Group type: COMPARATOR
Intervention: Mobility strategies (various types of exercise and muscle stimulation) in-hospital
Number of subjects: 4059

Group type: COMPARATOR
Intervention: Gait, balance and functional training in-hospital
Number of subjects: 4059

Group type: COMPARATOR
Intervention: Mobility strategies (various types of exercise) post-hospital
Number of subjects: 4059

Group type: COMPARATOR
Intervention: Training involving gait, balance and functional exercise post-hospital
Number of subjects: 4059

Group type: COMPARATOR
Intervention: Resistance or strength exercise post-hospital
Number of subjects: 4059

Group type: COMPARATOR
Intervention: Multiple intervention components post-hospital
Number of subjects: 4059
Study: 36070176

Group type: EXPERIMENTAL
Intervention: Quadrivalent inactivated split-virion influenza vaccine (QIV; Vaxigrip Tetra)
Number of subjects: 663
Study: 36070539

Group type: EXPERIMENTAL
Intervention: UCPVax (0.25 mg, 0.5 mg, and 1 mg)
Number of subjects: 59
Study: 36070540

Group type: EXPERIMENTAL
Intervention: Pafolacianine (0.025 mg/kg IV), given ≥ 1 hour before intraoperative near-infrared imaging
Number of subjects: 150
Study: 36070558

Group type: EXPERIMENTAL
Intervention: EBRT with LDR brachytherapy boost
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EBRT with a simultaneous integrated boost
Number of subjects: 0

Group type: COMPARATOR
Intervention: EBRT alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radical prostatectomy
Number of subjects: 0
Study: 36071122

Group type: EXPERIMENTAL
Intervention: 12-week exercise intervention including aerobic and strength training
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 12-week exercise intervention
Number of subjects: 13
Study: 36071311

Group type: EXPERIMENTAL
Intervention: Trifocal strategy
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Refractive bifocal strategy
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Blended strategy
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Diffractive bifocal strategy
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: EDOF strategy
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Monovision strategy
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Monofocal strategy
Number of subjects: 194

Group type: COMPARATOR
Intervention: Trifocal strategy compared to refractive bifocal strategy
Number of subjects: 194
Study: 36071389

Group type: EXPERIMENTAL
Intervention: 4 Pillars™ Practice Transformation Program
Number of subjects: 365
Study: 36071439

Group type: EXPERIMENTAL
Intervention: Hospital at Home (HaH-HA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional hospitalization (UC)
Number of subjects: 0
Study: 36071461

Group type: EXPERIMENTAL
Intervention: Immunoadsorption
Number of subjects: 42

Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 42
Study: 36072606

Group type: EXPERIMENTAL
Intervention: Controlled human malaria infection (CHMI) with homologous blood-stage parasites
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 36072887

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: A allele carriers
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: FTO genotype
Number of subjects: 105
Study: 36072945

Group type: EXPERIMENTAL
Intervention: Continuation of ART
Number of subjects: 0

Group type: COMPARATOR
Intervention: Analytic treatment interruption (ATI)
Number of subjects: 0
Study: 36072994

Group type: EXPERIMENTAL
Intervention: Burosumab (0.3, 0.6, or 1.0 mg/kg subcutaneous injection every 4 weeks, titrated at Week 12)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 0
Study: 36073247

Group type: EXPERIMENTAL
Intervention: Agalsidase beta treatment
Number of subjects: 0
Study: 36073629

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36073641

Group type: EXPERIMENTAL
Intervention: Patients with ACS and OSA
Number of subjects: 1174

Group type: COMPARATOR
Intervention: Patients without OSA
Number of subjects: 1174

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 1174
Study: 36073646

Group type: EXPERIMENTAL
Intervention: Symptomatic group (AFEQT score ≤80)
Number of subjects: 1515

Group type: COMPARATOR
Intervention: Asymptomatic group (AFEQT score >80)
Number of subjects: 1515
Study: 36073645

Group type: EXPERIMENTAL
Intervention: LA emptying fraction measured by transthoracic echocardiography
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: Indexed LA volumes
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: LA emptying fraction and indexed LA volumes
Number of subjects: 1866
Study: 36073648

Group type: EXPERIMENTAL
Intervention: Serum drug measurements
Number of subjects: 19

Group type: COMPARATOR
Intervention: Directly observed therapy
Number of subjects: 19
Study: 36074028

Group type: EXPERIMENTAL
Intervention: School of Health for Older People intervention
Number of subjects: 135

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 135
Study: 36074157

Group type: EXPERIMENTAL
Intervention: High adrenal uptake
Number of subjects: 15
Study: 36074545

Group type: EXPERIMENTAL
Intervention: Diabetes prevention intervention via smartphone app and group support
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 36074546

Group type: EXPERIMENTAL
Intervention: BEST4Baby app used by peer counselors (PCs) during home visits
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: BEST4Baby app
Number of subjects: 22